

Contents

Overview of progress: Dashboard from the Deloitte-Pharmacy Collaboration	2
P&T Motions to MAC for Approval	3
1. Motion: Request for approval by MAC for the following drugs to be added to the master formulary.....	3
2. Motion: Request for approval by MAC for the following drugs to be categorized as “Non-formulary (ie do NOT add to formulary)”:	6
3. Motion: Request for approval by MAC for the following drugs to be categorized “Do not build [in Odyssey]”:	10
4. Motion: Subject matter expert (SME) review of the following drugs requested by respective HHS Chiefs or Delegates for the following:	11
a. HHS Chief Subject Matter Expertise (SME) Requested– Drs. Khalid Azzam (Adult Medicine) and as denoted by “(+P)”, Angelo Mikrogianakis	11
Background Information for our Subject Matter Experts (SMEs)	13
Process Map for Expedited Formulary Review for Odyssey Build	14

Overview of progress: Dashboard from the Deloitte-Pharmacy Collaboration

PROJECT ODYSSEY | PHARMACY READINESS

Overall Status: **Late, but recoverable**

Dashboard | Formulary Approval Process

G On Track **Y** Late, but recoverable **R** Delayed, requires re-planning **C** Complete

High-level overview of Deloitte-provided lists and therapeutic classes, and the number of medications requiring review by all stakeholders. This dashboard is to be updated by Deloitte and HHS Pharmacy on an ongoing basis.

List *	Therapeutic Classes**	Meditech line items ***	Deloitte deliverable date/status	Initial Deloitte recommendations for HHS Pharmacy evaluation		HHS Pharmacy recommendations submitted to P&T		P&T reviewed and submitted to MAC	MAC Approved
List 1	• All oral medications	~1896	March 1, 2021 C	Top 80 th per centile non-formulary:	36 meds (119 line items)	Add to formulary: Build as non-formulary: Do not build SME review:	64 line items 32 line items 19 line items 19 line items	60 line items 7 line items 14 line items 20 line items	April 14, 2021
				Bottom 20 th per centile non-formulary:	121 meds (202 line items)	Add to formulary: Build as non-formulary: Do not build SME review:	76 line items 94 line items 9 line items 13 line items	76 line items 94 line items 9 line items 13 line items	
					155 meds (198 line items)	Add to formulary: Build as non-formulary: Do not build SME review:	TBD	TBD	
				Formulary:	107 meds (184 line items)	Keep as formulary	184 line items	[none deemed needed as currently formulary]	-
List 2	• Antihistamine Drugs • Blood Derivatives • Blood Formation, Coagulation and Thrombosis	~275 (excluding oral meds)	March 15, 2021 C	non-formulary:	7 meds (25 line items)	TBD	TBD	TBD	-
				Formulary:	28 meds (34 line items)	Add to formulary	34 line items	TBD	-
List 3	• Autonomic Drugs • Dental Agents • Respiratory Tract Agents • Electrolytic, Caloric, and Water Balance	~651 (excluding oral meds)	March 29, 2021 G	non-formulary:	-	-	-	-	-
				Formulary:	-	-	-	-	-
List 4	• Miscellaneous Therapeutic Agents	~675 (excluding oral meds)	April 12, 2021 G	non-formulary:	-	-	-	-	-
				Formulary:	-	-	-	-	-
List 5	• Central Nervous System Agents • Local Anesthetics	~4038 (excluding oral meds)	April 26, 2021 G	non-formulary:	-	-	-	-	-
				Formulary:	-	-	-	-	-

*Because List 1 contains all oral meds and following lists contain classes of all dosage forms, List 1 and following lists will have some overlap.

**The group of therapeutic classes within each list is based on pairing similar classes together and balancing the number of medications requiring review per list.

***Line item refers to every strength and formulation of a given drug in the Meditech drug dictionary. This is the approximate number of line items that Deloitte will be analyzing. This number is not reflective of the volume of medications that require review by HHS Pharmacy

P&T Motions to MAC for Approval

1. Motion: Request for approval by MAC for the following drugs to be added to the master formulary

REFERENCE NAME (MNEMONIC + GENERIC + TRADE + DOSE)	Avg Annual Rx's	Avg Annual Doses	Avg Annual \$	PandT review date
BECL1C BECLOMETHASONE 1mg CAP	36	1821	\$ 256	9-Apr-21
BETA16T BETAHISTINE SERC 16mg TAB	254	1460	\$ 91	9-Apr-21
BETA8TAB BETAHISTINE Auro-Betahistine 8mg TAB	151	3565	\$ 850	9-Apr-21
BUDE3C BUDESONIDE CR Entocort 3mg CAP	79	1869	\$ 4,050	9-Apr-21
CAPO.25UL CA 0.33mMOL/PO4 0.25mMOL/1ML CALCIUM PHOSPHATE ORAL 0.25ML LIQ.PO	1	1	\$ 0	9-Apr-21
CAPO4.5UL CA 0.33mMOL/PO4 0.25mMOL/1ML CALCIUM PHOSPHATE ORAL 0.5ML LIQ.PO	15	504	\$ 5	9-Apr-21
CAPO41UL CA 0.33mMOL/PO4 0.25mMOL/1ML CALCIUM PHOSPHATE ORAL 1mL LIQ.PO	37	1550	\$ 47	9-Apr-21
CAPO42UL CA 0.33mMOL/PO4 0.25mMOL/1ML CALCIUM PHOSPHATE ORAL 2mL LIQ.PO	16	825	\$ 44	9-Apr-21
CARV1.67UL CARVEDILOL Coreg 1.67mg/mL LIQ.PO	13	324	\$ 4	9-Apr-21
CARV12.5T CARVEDILOL Coreg 12.5mg TAB	4	172	\$ 15	9-Apr-21
CARV25T CARVEDILOL Coreg 25mg TAB	90	903	\$ 68	9-Apr-21
CARV3125T CARVEDILOL Coreg 3.125mg TAB	126	1116	\$ 33	9-Apr-21
CARV625T CARVEDILOL Coreg 6.25MG TAB	267	2776	\$ 123	9-Apr-21
CLOB10T cloBAZam Frisium 10mg TAB	317	3423	\$ 325	9-Apr-21
CLOB2.5T cloBAZam Frisium 2.5mg TAB.SPLIT	39	217	\$ 6	9-Apr-21
CLOB5T cloBAZam Frisium 5mg TAB.SPLIT	100	713	\$ 48	9-Apr-21
CLON0.2T cloNIDine Apo-Clonidine 0.2mg TAB	55	265	\$ 67	9-Apr-21
CLON025T cloNIDine Catapres,Dixarit 0.025mg TAB	208	1083	\$ 501	9-Apr-21
ENTAC100T ENTACAPONE Comtan 100mg TAB.SPLIT	2	43	\$ 9	9-Apr-21
ENTAC200T ENTACAPONE Comtan 200mg TAB	72	3078	\$ 643	9-Apr-21
LOXA10T LOXAPINE Loxapac 10mg TAB	74	2747	\$ 888	9-Apr-21
LOXA25T LOXAPINE Loxapac 25mg TAB	33	254	\$ 158	9-Apr-21

Pharmacy and Therapeutics Committee

Recommendations to the Medical Advisory Committee (MAC)

From the TRANSformulary clean-up meetings held Apr 9 and 26th, 2021

LOXA50T LOXAPINE Loxapac 50mg TAB	2	0	\$ -	9-Apr-21
LOXAP25T LOXAPINE Xylac 2.5mg TAB	15	218	\$ 68	9-Apr-21
METHO125T Methotrimeprazine Nozinan 12.5mg TAB.SPLIT	12	95	\$ 11	9-Apr-21
METHO2.5T Methotrimeprazine Nozinan 2.5mg TAB.SPLIT	3	6	\$ 0	9-Apr-21
METHO25T Methotrimeprazine Nozinan 25mg TAB	42	445	\$ 167	9-Apr-21
METHO2T Methotrimeprazine Nozinan 2mg TAB	16	1475	\$ 146	9-Apr-21
METHO50T Methotrimeprazine Nozinan 50mg TAB	7	2	\$ 1	9-Apr-21
METHO5T Methotrimeprazine Nozinan 5mg TAB	211	3000	\$ 603	9-Apr-21
METHO625T Methotrimeprazine Nozinan 6.25mg TAB.SPLIT	3	4	\$ 0	9-Apr-21
OXCA150T OXcarbazepine Trileptal 150mg TAB	29	686	\$ 504	9-Apr-21
OXCA300T OXcarbazepine Trileptal 300mg TAB	53	1105	\$ 1,654	9-Apr-21
OXCA600T OXcarbazepine Trileptal 600mg TAB	16	109	\$ 228	9-Apr-21
OXCAUL OXcarbazepine Trileptal 60mg/1mL LIQ.PO	42	428	\$ 1,040	9-Apr-21
PENTC VITA 3B * VIT B12/PYRIDOXINE HCL/VIT B1 1TAB TAB	314	3985	\$ 881	9-Apr-21
PRAM05T PRAMIPEXOLE Mirapex 0.5mg TAB	89	1149	\$ 256	9-Apr-21
PRAM125T PRAMIPEXOLE Mirapex 0.125mg TAB	24	319	\$ 398	9-Apr-21
PRAM1T PRAMIPEXOLE Mirapex 1mg TAB	53	629	\$ 90	9-Apr-21
PRAM25T PRAMIPEXOLE Mirapex 0.25mg TAB	271	3379	\$ 276	9-Apr-21
RISP0.5UL RisperiDONE RisperDAL Solution ,Apo-Risperidone) 0.5mg/0.5mL LIQ.PO	6	387	\$ 23	9-Apr-21
RISPUL RisperiDONE RisperDAL Solution ,Apo-Risperidone) 1mg/1mL LIQ.PO	86	1541	\$ 97	9-Apr-21
SELE100T9 SELENIUM Selenium 100mcg TAB	131	1884	\$ 291	9-Apr-21
SELE200T SELENIUM Selenium 200mcg TAB	164	1762	\$ 87	9-Apr-21
SELEUL SELENIUM Selepen 40mcg/1mL LIQ.PO	14	134	\$ 0	9-Apr-21
SEVE800T SEVELAMER Renagel 800mg TAB	67	1099	\$ 2,912	9-Apr-21
SILDUL SILDENAFIL SUSP Viagra suspension 2.5mg/mL LIQ.PO	38	1491	\$ 230	9-Apr-21
SIN10025CR SINEMET CR 100/25 LEVODOPA/CARBIDOPA 100/25 MG CR 1TAB TAB.CR	66	1147	\$ 358	9-Apr-21
SIN20050CR SINEMET CR 200/50 LEVODOPA/CARBIDOPA 200/50 MG CR 1TAB TAB.CR	58	928	\$ 487	9-Apr-21

Pharmacy and Therapeutics Committee

Recommendations to the Medical Advisory Committee (MAC)

From the TRANSformulary clean-up meetings held Apr 9 and 26th, 2021

TOPI100T TOPIRAMATE Topamax 100mg TAB	208	2293	\$ 200	9-Apr-21
TOPI125T TOPIRAMATE Topamax 12.5mg TAB.SPLIT	1	3	\$ 0	9-Apr-21
TOPI25T TOPIRAMATE Topamax 25mg TAB	298	3756	\$ 1,914	9-Apr-21
TOPIUL TOPIRAMATE ORAL SUSP 6mg/mL LIQ.PO	44	369	\$ 95	9-Apr-21
TRAN05C TRANDOLAPRIL Mavik 0.5mg CAP	4	19	\$ 0	9-Apr-21
TRAN1C TRANDOLAPRIL Mavik 1mg CAP	52	376	\$ 8	9-Apr-21
TRAN2C TRANDOLAPRIL Mavik 2mg CAP	178	1107	\$ 45	9-Apr-21
TRAN4C TRANDOLAPRIL Mavik 4mg CAP	1	0	\$ -	9-Apr-21
BACL20T BACLOFEN Gen-Baclofen, Lioresal Ds 20mg TAB	211	7647	\$ 291	23-Apr-21
SILO8CAP SILODOSIN Rapaflo 8mg CAP	167	2067	\$ 1,188	23-Apr-21
SILO4CAP SILODOSIN Rapaflo 4mg CAP	94	1069	\$ 647	23-Apr-21
TIZA4T tiZANidine Apo-Tizanidine, Zanaflex 4mg TAB	64	2815	\$ 2,553	23-Apr-21
GLYCOUL GLYCOPYRROLATE SUSP Glycopyrrolate 0.1mg/mL LIQ.PO	55	1394	\$ 148	23-Apr-21
CIPRUL CIPROFLOXACIN SUSP Cipro Oral Suspension 100mg/mL LIQ.PO	35	217	\$ 522	23-Apr-21
TEMO100C TEMOZOLOMIDE Temodal 100mg CAP	25	205	\$ 4,041	23-Apr-21
TEMO20C TEMOZOLOMIDE Temodal 20mg CAP	24	179	\$ 1,287	23-Apr-21
TEMO5C TEMOZOLOMIDE Temodal 5mg CAP	19	121	\$ 280	23-Apr-21
PYRA500T PYRAZINAMIDE Tebrazid 500mg TAB	14	97	\$ 254	23-Apr-21
VITD50C VITAMIN D 50000unit CAP	103	306	\$ 149	23-Apr-21
VERA240SR VERAPAMIL SLOW RELEASE Ispoptin SR, Apo-Verap SR 240mg TAB.SR	28	165	\$ 22	23-Apr-21
VERA120SR VERAPAMIL SLOW RELEASE Isoptin SR 120mg TAB.SR	17	71	\$ 7	23-Apr-21
VERA180SR VERAPAMIL SLOW RELEASE Isoptin SR 180mg TAB.SR	17	276	\$ 49	23-Apr-21
VALGUL valGANciclovir Valcyte Suspension 50mg/mL LIQ.PO	19	153	\$ 4,272	23-Apr-21
IVER3TAB IVERMECTIN Stromectol 3mg TAB	13	15	\$ 399	23-Apr-21
ATOV250T2 MALARONE Atavaquone/Proguanil HCl 1TAB TAB	13	29	\$ 249	23-Apr-21
SILD25T SILDENAFIL Viagra 25mg TAB	12	136	\$ 37	23-Apr-21

2. Motion: Request for approval by MAC for the following drugs to be categorized as “Non-formulary (ie do NOT add to formulary)”:

REFERENCE NAME (MNEMONIC + GENERIC + TRADE + DOSE)	Avg Annual Rx's	Avg Annual Doses	Avg Annual \$	PandT review date
VITALUXA VITALUX ADVANCED Vitalux ADVANCED 1TAB TAB	75	1554	\$ 389	9-Apr-21
MOXI400T MOXIFLOXACIN Avelox 400mg TAB	157	398	\$ 370	23-Apr-21
TEMA15C TEMAZEPAM Restoril, Apo-Temazepam, Pms-Temazepam 15mg CAP	229	941	\$ 55	23-Apr-21
TOLT2SR TOLTERODINE ER Detrol LA, Unidet 2mg CAP	187	1220	\$ 756	23-Apr-21
FESO4TAB FESOTERODINE ER Toviaz 4mg TAB.ER	180	1366	\$ 2,531	23-Apr-21
SOLI5T SOLIFENACIN SUCCINATE Vesicare 5mg TAB	162	1352	\$ 230	23-Apr-21
QUIN20T QUINAPRIL Accupril 20mg TAB	159	931	\$ 490	23-Apr-21
FENO160T FENOFIBRATE SUPRA MICROCOATED Lipidil Supra 160mg TAB	152	1290	\$ 906	23-Apr-21
ALFU10T ALFUZOSIN Xatral 10mg TAB.PR	130	1011	\$ 162	23-Apr-21
BUME1T BUMETANIDE Burinex 1mg TAB	125	693	\$ 1,977	23-Apr-21
OMEP20C OMEPRAZOLE Apo-Omeprazole 20mg CAP	121	1180	\$ 210	23-Apr-21
CODE50T CODEINE CONTIN CR Codeine Contin 50mg TAB.CR	114	494	\$ 286	23-Apr-21
LANS30C LANSOPRAZOLE Prevacid 30mg CAP	108	5186	\$ 509	23-Apr-21
TOLT2T TOLTERODINE Detrol 2mg TAB	98	997	\$ 240	23-Apr-21
ROPI25T rOPINIRole Requip 0.25mg TAB	94	982	\$ 109	23-Apr-21
DYAZT DYAZIDE TRIAMTERENE/HCTZ 50 / 25 mg 1TAB TAB	92	575	\$ 19	23-Apr-21
GRAN1T GRANISETRON Kytril 1mg TAB	89	248	\$ 2,411	23-Apr-21
AMIL5T aMILoride Midamor 5mg TAB	86	799	\$ 236	23-Apr-21
GUAN1TAB GUANFACINE Intuniv XR 1mg TAB.ER	77	332	\$ 2,648	23-Apr-21
QUIN10T QUINAPRIL Accupril 10mg TAB	77	526	\$ 214	23-Apr-21

Pharmacy and Therapeutics Committee

Recommendations to the Medical Advisory Committee (MAC)

From the TRANSformulary clean-up meetings held Apr 9 and 26th, 2021

TRAM50TA2 traMADol Ultram 50mg TAB	64	995	\$ 220	23-Apr-21
MAGN30UL Magnesium Hydroxide/Min Oil Magnolax 30mL LIQ.PO	59	69	\$ 27	23-Apr-21
FENO200C FENOFIBRATE (MICRONIZED) Lipidil Micro , Gen-Fenofibrate 200mg CAP	55	447	\$ 90	23-Apr-21
LEFL20T LEFLUNOMIDE Arava 20mg TAB	55	380	\$ 342	23-Apr-21
ZINCUL ZINC SOLUTION Zinc Sulfate Solution 10mg/mL LIQ.PO	54	1379	\$ 24	23-Apr-21
FLUV50T fluvoxAMINE Apo-Fluvoxamine, Luvox 50mg TAB	51	402	\$ 78	23-Apr-21
ENAL20T ENALAPRIL Vasotec, Apo Enalapril 20mg TAB	51	379	\$ 20	23-Apr-21
DESV50TA DESVENLAFAXINE Pristiq 50mg TAB.ER	50	327	\$ 1,001	23-Apr-21
DIAZ10UL DIAZOXIDE SUSPENSION Proglycem Suspension 10mg/mL LIQ.PO	47	663	\$ 2,713	23-Apr-21
METO100SR METOPROLOL SR Lopresor SR 100mg TAB.SR	47	211	\$ 47	23-Apr-21
ROPI1T rOPINIRole Requip 1mg TAB	45	320	\$ 55	23-Apr-21
ARTH50T ARTHROTEC 50 Diclofenac Sodium/Misoprostol 1TAB TAB	42	502	\$ 247	23-Apr-21
MEMA10T MEMANTINE Ebixa 10mg TAB	42	974	\$ 54	23-Apr-21
LEFL10T LEFLUNOMIDE Arava 10mg TAB	41	471	\$ 77	23-Apr-21
FESO8TAB FESOTERODINE ER Toviaz 8mg TAB.ER	38	401	\$ 635	23-Apr-21
VIGA500T VIGABATRIN Sabril 500mg TAB	38	258	\$ 369	23-Apr-21
FOSI10T FOSINOPRIL Monopril 10mg TAB	36	157	\$ 31	23-Apr-21
NALO25TA NALOXEGOL Movantik 25mg TAB	36	209	\$ 1,115	23-Apr-21
FEBU80TA FEBUXOSTAT Uloric 80mg TAB	35	275	\$ 692	23-Apr-21
LINA145C LINACLOTIDE Constella 145mcg CAP	35	248	\$ 1,500	23-Apr-21
CODE100CR CODEINE CONTIN CR Codeine Contin CR 100mg TAB.CR	35	155	\$ 149	23-Apr-21
PRUC2TAB PRUCALOPRIDE Resotran 2mg TAB	34	351	\$ 1,212	23-Apr-21
COEN30C COENZYME Q10 Coenzyme Q10 30mg CAP	33	1311	\$ 358	23-Apr-21
BROM3T BROMAZEPAM LECTOPAM, Novo-Bromazepam, 3mg TAB	32	254	\$ 7	23-Apr-21
TETR25T TETRABENAZINE Nitoman 25mg TAB	32	427	\$ 287	23-Apr-21
ACEB100T ACEBUTOLOL Monitan, Sectral, Rhotral 100mg TAB	32	307	\$ 28	23-Apr-21
METHO500T METHOCARBAMOL Robaxin 500mg TAB	32	312	\$ 306	23-Apr-21

Pharmacy and Therapeutics Committee

Recommendations to the Medical Advisory Committee (MAC)

From the TRANSformulary clean-up meetings held Apr 9 and 26th, 2021

VORT10T VORTIOXETINE HYDROBROMIDE TRINTELLIX 10mg TAB	31	187	\$ 661	23-Apr-21
MESA1.2T MESALAMINE (MEZAVANT) Mezavant 1200mg TAB.DR	30	211	\$ 820	23-Apr-21
PRUC1TAB PRUCALOPRIDE Resotran 1mg TAB	29	180	\$ 383	23-Apr-21
ATOM10CA ATOMOXETINE Strattera 10mg CAP	28	119	\$ 154	23-Apr-21
PANC20EC PANCRELIPASE ECS 20 LIPASE/PROTEASE/AMYLASE 1CAP CAP	27	372	\$ 706	23-Apr-21
NALT50T NALTREXONE Revia 50mg TAB	26	112	\$ 570	23-Apr-21
DICY10T DICYCLOMINE Bentytol, Formulex 10MG TAB	26	254	\$ 70	23-Apr-21
PINA50T PINAVERIUM BROMIDE Dicetel 50mg TAB	25	472	\$ 202	23-Apr-21
VIT1500S PEDIA-VIT Pediavit Soln, TRI-VI-SOL 1mL LIQ.PO	25	428	\$ 73	23-Apr-21
SAXA5TAB sAXaglipitin Onglyza 5mg TAB	24	161	\$ 454	23-Apr-21
ACEB200T ACEBUTOLOL Monitan, Sectral, Rhotral 200mg TAB	24	213	\$ 21	23-Apr-21
BUSP10T busPIRone Buspar 10mg TAB	24	272	\$ 15	23-Apr-21
LOVA20T LOVASTATIN Gen-Lovastatin, Apo-Lovastatin, Mevacor 20mg TAB	23	156	\$ 27	23-Apr-21
LURA20TA LURASIDONE Latuda 20mg TAB	22	108	\$ 837	23-Apr-21
CILA5T CILAZAPRIL Inhibace 5 5mg TAB	21	187	\$ 31	23-Apr-21
ESTR1T ESTRADIOL Estrace 1mg TAB	20	116	\$ 86	23-Apr-21
RUF1100T RUFINAMIDE Banzel 100mg TAB	20	179	\$ 705	23-Apr-21
LURA40TA LURASIDONE Latuda 40mg TAB	19	233	\$ 990	23-Apr-21
BEZA400SR BEZAFIBRATE Bezalip SR 400mg TAB.SR	18	109	\$ 193	23-Apr-21
FLUV20C FLUVASTATIN Lescol 20mg CAP	18	71	\$ 29	23-Apr-21
PALI3TAB PALIPERIDONE Invega 3mg TAB.ER	18	161	\$ 1,179	23-Apr-21
TRAM100T2 traMADol Ralivia 100mg TAB.ER	18	61	\$ 159	23-Apr-21
LOVA40T LOVASTATIN Gen-Lovastatin, Mevacor, Apo-Lovastatin 40mg TAB	18	207	\$ 100	23-Apr-21
PANC8EC PANCRELIPASE ECS 8 LIPASE/PROTEASE/AMYLASE 1CAP CAP	18	295	\$ 177	23-Apr-21
SILD20TA4 SILDENAFIL REVATIO 20mg TAB	18	434	\$ 183	23-Apr-21
ARTH75T ARTHROTEC 75 Diclofenac Sodium/Misoprostol 1TAB TAB	17	863	\$ 556	23-Apr-21
LIP0100C ALPHA LIPOIC ACID ALPHA LIPOIC ACID 100mg CAP	17	287	\$ 54	23-Apr-21

Pharmacy and Therapeutics Committee

Recommendations to the Medical Advisory Committee (MAC)

From the TRANSformulary clean-up meetings held Apr 9 and 26th, 2021

SELE5T SELEGILINE Eldepryl, Deprenyl 5mg TAB	17	537	\$ 54	23-Apr-21
TOLT1T TOLTERODINE Detrol 1mg TAB	17	171	\$ 34	23-Apr-21
LEVOUL levOCARNitine SOLUTION Carnitor 100mg/mL LIQ.PO	16	239	\$ 204	23-Apr-21
QUIN5T QUINAPRIL Accupril 5mg TAB	16	86	\$ 26	23-Apr-21
TERB250T TERBINAFINE LamISIL 250mg TAB	15	128	\$ 34	23-Apr-21
FOSI20T FOSINOPRIL Monopril 20mg TAB	14	98	\$ 13	23-Apr-21
GLYC100BL GLYCERINE 1ML LIQ.PO	14	25	\$ 31	23-Apr-21
LANS15C LANSOPRAZOLE Prevacid 15mg CAP	14	21	\$ 1	23-Apr-21
ISOS60SR ISOSORBIDE MONONITRATE Imdur 60mg TAB.ER	13	190	\$ 21	23-Apr-21
THYR30T THYROID, DESSICATED Thyroid 30mg TAB	13	54	\$ 22	23-Apr-21
FELO10T FELODIPINE ER Plendil, Renedil 10mg TAB	13	112	\$ 49	23-Apr-21
PEPTUL BISMUTH SUBSALICYLATE Pepto Bismol 1mL LIQ.PO	13	227	\$ 115	23-Apr-21
FAMP10TA FAMPRIDINE Fampyra 10MG TAB.ER	12	253	\$ 2,595	23-Apr-21
AMYL60TA PANCRELIPASE 20,880 USP Viokace 1TAB TAB	12	447	\$ 459	23-Apr-21
CINA30TA CINACALCET Sensipar 30mg TAB	12	93	\$ 222	23-Apr-21
FELO5T FELODIPINE ER Plendil, Renedil 5mg TAB	11	61	\$ 22	23-Apr-21
PROL10025C PROLOPA 100-25 BENSERAZIDE 25mg/LEVODOPA 100mg 100mg/25mg CAP	11	241	\$ 138	23-Apr-21
ABAC600T TRIUMEQ 600/50/300 mg Abacavir/Dolutegravir/Lamivudine 600/50/300mg 1TAB TAB	11	47	\$ 2,102	9-Apr-21
DOLU50TA DOLUTEGRAVIR Tivicay 50mg TAB	22	197	\$ 4,074	23-Apr-21
MINO50C MINOCYCLINE Apo-Minocycline, Minocin 50mg CAP	19	132	\$ 25	23-Apr-21

Pharmacy and Therapeutics Committee

Recommendations to the Medical Advisory Committee (MAC)

From the TRANSformulary clean-up meetings held Apr 9 and 26th, 2021

3. Motion: Request for approval by MAC for the following drugs to be categorized “Do not build [in Odyssey]”:

REFERENCE NAME (MNEMONIC + GENERIC + TRADE + DOSE)	Avg Annual Rx's	Avg Annual Doses	Avg Annual \$	PandT review date
RABE20T RABEprazole Pariet 20mg TAB	11	57	\$ 4	23-Apr-21
BEADSDIL DRUG ELUTING BEADS & DILUENT 1mL ML	45	38	\$ -	23-Apr-21
LORA1T LORazepam Ativan, Apo-Lorazepam 1mg TAB	13	16	\$ 0	23-Apr-21
FAMC500T FAMCICLOVIR Famvir 500mg TAB	15	264	\$ 201	23-Apr-21
RIBO100T RIBOFLAVIN Vitamin B2 100mg TAB	14	123	\$ 18	23-Apr-21
LORA10T LORATADINE Claritin 10mg TAB	142	2053	\$ 1,081	23-Apr-21
CRAN7500T CRANBERRY CRAN-MAX 250mg 1TAB TAB	20	403	\$ 96	23-Apr-21
RISP1TAB RisperiDONE DISINTEGRATING RisperDAL M 1mg TAB	2	2	\$ 1	9-Apr-21
RISP5DT RisperiDONE DISINTEGRATING RisperDAL M 0.5mg TAB	3	1	\$ 0	9-Apr-21

Pharmacy and Therapeutics Committee

Recommendations to the Medical Advisory Committee (MAC)


From the TRANSformulary clean-up meetings held Apr 9 and 26th, 2021

4. Motion: Subject matter expert (SME) review of the following drugs requested by respective HHS Chiefs or Delegates for the following:

a. HHS Chief Subject Matter Expertise (SME) Requested– Drs. Khalid Azzam (Adult Medicine) and as denoted by “(+P)”, Angelo Mikrogianakis

Drug (generic name, trade name, strength, units)	Avg Ann ual Rxs	Avg Annual Doses	Avg Annual \$	Suggested SME Service(s)	Approve for formulary	Approve for formulary, <i>restricted</i>	Approve as <i>non- formulary</i>	Do not build	Comments
TACR1CAP TACROLIMUS ER Advagraf 1mg CAP.ER	62	386	\$6251	Nephrology	☐	☐	☐	☐	
TACR3CAP TACROLIMUS ER Advagraf 3mg CAP.ER	37	239			☐	☐	☐	☐	
TACR0.5C TACROLIMUS ER Advagraf 0.5mg CAP.ER	28	162			☐	☐	☐	☐	
TACR5CAP TACROLIMUS ER Advagraf 5mg CAP.ER	15	112			☐	☐	☐	☐	
Notes	PandT recommends review and reconciliation of recent submission for addition to formulary at St. Joe’s for Tacrolimus PA (Envarsus PA)								

Drug (generic name, trade name, strength, units)	Avg Annual Rx's	Avg Annual Doses	Avg Annual \$	Suggested SME Service(s)	Approve for formulary	Approve for formulary, <i>restricted</i>	Approve as <i>non-formulary</i>	Do not build	Comments
MODA100T MODAFINIL Alertec 100mg TAB	52	587	\$ 100	Neurology	☐	☐	☐	☐	
METHY20SR METHYLPHENIDATE SR Ritalin SR 20mg TAB	61	373	\$ 76	Neurology	☐	☐	☐	☐	
METH50CS METHYLPHENIDATE CR (BIPHENTIN) Biphentin 50 mg 50mg CAP.CR (+P)	14	49	\$ 162	Neurology	☐	☐	☐	☐	
METH20CS METHYLPHENIDATE CR (BIPHENTIN) Biphentin 20 mg 20mg CAP.CR (+P)	36	169	\$ 381	Neurology	☐	☐	☐	☐	



METH10CS METHYLPHENIDATE CR (BIPHENTIN) Biphen 10 mg 10mg CAP.CR (+P)	17	67	\$ 63	Neurology	☐	☐	☐	☐	
LISD30CA LISDEXAMFETAMINE Vyvanse 30mg CAP (+P)	70	164	\$ 704	Neurology	☐	☐	☐	☐	
LISD20CA LISDEXAMFETAMINE Vyvanse 20mg CAP (+P)	85	189	\$ 837	Neurology	☐	☐	☐	☐	
LISD10CA LISDEXAMFETAMINE Vyvanse 10mg CAP (+P)	15	33	\$ 82	Neurology	☐	☐	☐	☐	
CAFF100T CAFFEINE Wake Ups 100mg TAB	38	170	\$ 15	Neurology	☐	☐	☐	☐	
Notes	PandT noted relatively low but consistent usage of these non-formulary stimulants.								

Background Information for our Subject Matter Experts (SMEs)

Dear Dr. Chief or Subject Matter Expert,

As part of ongoing preparations for the Odyssey build, the Pharmacy and Therapeutics Committee (PTC) is performing a formulary review in collaboration with the consulting firm Deloitte, and as endorsed by MAC.

As part of this review, select *non-formulary* drugs that are either high-cost OR for which their use-case is unclear have been identified by PTC. PTC is recommending subject matter expert (SME) review of these drugs as part of an expedited review process. In this case “high-cost” has been defined as fiscal expenditures of greater than \$5K annually. Most of these drugs have been in use over the past 2 fiscal years, but have not been submitted to PTC for consideration for addition to formulary.

We have are requesting subject matter expertise expedited review to ensure that consideration as been given to current formulary drugs or alternatives within your specialty. Drugs used significantly in both adults and pediatrics will be flagged for review by more than one Chief. The symbols **(+P)** will be flagged beside drug names with more use in adults and with **(+A)** if used more in pediatrics.

We are requesting that yourself or a delegated subject matter expert review these drugs and make recommendations as follows:

Recommendation	Explanation and notes
Approve for master formulary addition, unrestricted	These will be built in Odyssey, available to all prescribers
Approve for master formulary addition, restricted	These will be built in Odyssey, but may only be available to certain site(s) or prescriber groups (ie oncology, nephrology ,ID etc) . We are awaiting details Odyssey about how restricted access functions.
Approve to build as <i>non-formulary</i>	These will be built in Odyssey, but requires an authorization process before dispensing
Do not build	These will not be built in Odyssey and will be relatively unavailable to prescribers

Process Map for Expedited Formulary Review for Odyssey Build

